SARS-CoV-2/COVID-19: Clinical Course Among Subjects HIV-1-Infected in Sao Paulo

Autor(es):Mostrar menos -

Monteiro, Mariana A. A. ; Prates, Gabriela S. S. ; de Lima Nascimento, Najara A. A. ; Veiga, Ana Paula R. ; Magri, Marcello M. C. ; Polis, Thales J. B. ; Gascon, Maria R. P. ; Ferreira, Mauricio D. D. ; Tiberto, Larissa ; Pereira, Luisa O. O. ; Alves, Wagner ; Fonseca, Luiz A. M. ; Duarte, Alberto J. S. ; Casseb, Jorge

• Tipo de documento: Artigo Científico
• Fonte: CURRENT HIV RESEARCH; v. 20, n. 6, p. 6-pg., 2022-01-01.

Resumo

Introduction: People living with Human Immunodeficiency Virus (HIV) are under risk for co-infection with SARS-CoV-2. This population may be more prone to complications from COVID-19 due to persistent inflammation caused by HIV and higher incidence of metabolic syndromes, cardiovascular diseases, and malignancies, as well as being considered elderly at 50 years of age. The objective of this study was to report SARS-CoV-2 infection frequency, clinical evolution, and mortality in HIV-positive patients on antiretroviral therapy. Methods: The period of inquiry ranged from January to September 2020. Due to the social distance and the suspension of in-person medical care during the time of the investigation, we sent electronic questions about demographic, epidemiological, and clinical data to 403 HIV-infected patients. Results: Among 260 patients who answered the questionnaire, thirty-nine patients (15%) had suggestive symptoms and were tested for SARS-CoV-2 infection. Of this, 11 had positive results (32.4%) and no patient died of COVID-19 complications. Nine were male (3.4%), and the mean age of the patients with positive results was 43.2 years (+/- 9.6). 107 patients (41.1%) were over 50 years of age and their mean T-CD4(+) cell count was 768. Eleven patients (4.2%) had a detectable HIV RNA viral load and 127 (48.8%) had comorbidities. These variables were not associated with an increased risk for infection. Conclusion: The frequency of SARS-COV2 infection among HIV-infected is similar to the general population, and the clinical course is associated with the presence of comorbidities and not due to the HIV infection. However, new studies should be done to assess if this vulnerable population could answer the vaccine anti-SARS-Cov2. (AU)

• Processo FAPESP: 20/05984-2 - Manifestações neurológicas agudas associadas ao vírus SARS-CoV-2
• Beneficiário: Jorge Simao do Rosario Casseb
• Modalidade de apoio: Auxílio à Pesquisa - Regular